Objective: The purpose of this paper is to review the literature on insomnia in patients with heart disease in order to answer the following questions: (a) What is the impact of insomnia on quality of life, morbidity, and mortality in patients with heart disease? (b) What is the impact of treatment interventions on insomnia in patients with heart disease? Methods: Following the PRISMA guidelines, studies published from 1973 to 2023 that pertain to insomnia and heart disease were identified through the use of the PubMed and PsycINFO databases, using the keywords: ‘cardiac’ OR ‘cardiovascular’ OR ‘heart’ AND ‘disease’ AND ‘insomnia’. Two authors independently conducted a focused analysis and reached a final consensus on 11 studies that met the specific selection criteria and passed the study quality checks. Results: Management of insomnia in patients with heart disease involved combining different interventions, such as CBT-I with disease management or self-management programs, which demonstrated sustained improvements in sleep-related metrics in patients with heart disease and insomnia. While non-pharmacological approaches were the primary focus in most studies reviewed, medication-based interventions, such as zolpidem controlled-release, melatonin, and oxazepam, showed promising results. Conclusion: The findings support the use of CBT-I as an effective non-pharmacological approach for managing insomnia in patients with heart disease. Future research should explore the long-term effects of interventions, optimal dosing and duration, and potential synergistic effects of combining different interventions.